Cover Image
市場調查報告書

醫藥品主要企業系列:主要學名藥廠商 2015-2025

Pharma Leader Series: Top Generic Drug Producers - Leading Companies and Forecasts 2015-2025, Prospects for Development, Manufacturing and Business Expansion

出版商 Visiongain Ltd 商品編碼 335356
出版日期 內容資訊 英文 231 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
醫藥品主要企業系列:主要學名藥廠商 2015-2025 Pharma Leader Series: Top Generic Drug Producers - Leading Companies and Forecasts 2015-2025, Prospects for Development, Manufacturing and Business Expansion
出版日期: 2015年07月14日 內容資訊: 英文 231 Pages
簡介

本報告提供全球43家主要學名藥廠商公司的簡介,為您彙整其活動,技術及近幾年的財務實際成果議論,M&A,新產品,展望,課題及計劃等的發展的評估,學名藥收益的預測 (主要19家公司) 等資料。

第1章 調查概要

第2章 前50大學名藥廠商企業

  • 前50大學名藥廠商:收益·排行榜
  • 前50大學名藥廠商:收益分析
  • 前50大學名藥廠商的地區分佈
  • 調查範圍
  • 調查的複雜性

第3章 北美的主要學名藥廠商:活動·展望

  • 本章對象企業
  • 美國的主要學名藥廠商:財務實際成果概要
  • Mylan - 美國第1位學名藥廠商:企業概要
  • Pfize - 研究開發意向型的主要醫藥品企業:企業概要
  • Abbott:企業概要
  • Hospira:企業概要
  • Apotex:企業概要
  • Par Pharmaceuticals:企業概要
  • Valeant Pharmaceuticals:企業概要
  • Endo Pharmaceuticals:企業概要
  • Pharmascience - 加拿大的主要企業:企業概要
  • Akorn Pharmaceuticals:企業概要
  • Alvogen - 民間擁有的美國企業,熱門企業之一:企業概要
  • Sagent Pharmaceuticals - 美國專門學名藥的急速成長供應商之一

第4章 歐洲的主要學名藥廠商:活動·展望

  • 本章對象企業
  • 歐洲的主要學名藥廠商:財務實際成果概要
  • CEE (中東歐) 市場是許多大非專利競爭企業的據點
  • Novartis (Sandoz) - 全球第2位的學名藥企業:概要
  • Actavis:企業概要
  • Sanofi:企業概要
  • Fresenius Kabi - 主要非專利點滴藥企業:企業概要
  • Pharmstandard - 俄羅斯最大的醫藥品廠商:企業概要
  • Gedeon Richter - 最具前瞻性的匈牙利領導企業
  • Krka - 70個國家以上活動的斯洛維尼亞非專利巨大企業:企業概要
  • Stada 在Arzneimittel - 德國·中歐中佔有相當大佔有率:企業概要
  • Perrigo:企業概要
  • Polpharma - 波蘭的學名藥powerhouse:企業概要

第5章 印度的主要學名藥廠商:活動·展望

  • 本章對象企業
  • 印度:全球學名藥供應商
  • 印度的學名藥廠商前十大企業:財務實際成果概要
  • Sun Pharmaceutical - 印度的學名藥市場上領導者:企業概要
  • Dr. Reddy's Laboratories:企業概要
  • Lupin - 美國市場上最成功的印度的學名藥企業:企業概要
  • 在Cipla - 孟買設置據點的學名藥巨大企業:企業概要
  • 以Ranbaxy - 150個國家以上銷售的印度第2位的學名藥廠商:企業概要
  • Aurobindo - 最大的FDA API供應商,首發醫藥品的轉變:企業概要
  • Glenmark - 至今仍維繫學名藥的成長的專業公司
  • 擴大:企業概要Wockhardt - 美國·歐洲的學名藥市場上的佔有率
  • Cadila - 印度的心血管市場上領導企業:企業概要
  • Ipca Laboratories - 印度醫藥品出口企業的前十大企業之一:企業概要

第6章 其他地區的主要學名藥廠商:活動·展望

  • 本章對象企業
  • 其他地區的主要學名藥廠商:財務實際成果概要
  • 日本·巴西的學名藥環境,對全球學名藥市場來說尤為重要
  • Teva Pharmaceutical Industries - 全球學名藥產業的領導企業:企業概要
  • 領導:企業概要EMS - 南美的學名藥市場
  • Aspen Pharmacare - 持續擴大的南非巨大企業:企業概要
  • Nichi-Iko Pharmaceutical:企業概要
  • Abdi Ibrahim - 土耳其的主要醫藥品企業
  • Hypermarcas SA - 巴西的醫藥品·OTC巨大企業:企業概要
  • 在Eurofarma - 巴西中急速成長的學名藥企業:企業概要
  • Taro Pharmaceuticals - 第2位的以色列醫藥品廠商:企業概要
  • 東和藥品 - 日本的大企業之一:企業概要
  • 澤井製藥 - 大阪放置據點的學名藥的領導者:企業概要

第7章 調查採訪

第8章 結論

圖表清單

目錄
Product Code: PHA0055

Generic Drug Producers - Discover Top Companies' Revenue Prospects Now, Benefiting Your Influence

What does the future hold for manufacturers and sellers of generic medicines? Visiongain's new report shows you leading companies' prospects to 2025. That study lets you discover results, trends, opportunities and revenue forecasts, helping you stay ahead in knowledge.

For leading producers and marketers of generic drugs, you find information on established and rising companies. Explore their sales potentials in the generics market, seeing from 2015 to 2025 the prospects of industry leaders. What revenues are possible?

Sales predictions and other data to help you stay ahead in competitive intelligence

In our study you find analytical profiles of top generics producers. By region you analyse historical data, activities, revenue forecasts and growth rates. Discover qualitative analysis too. That work gives you 82 tables, 87 charts and two interviews with the industry.

Our new analysis shows you the most lucrative parts of the world industry for generic drugs. See today how you can benefit your research, analyses, decisions, proposals and presentations, also saving time and benefiting your reputation for insight.

Assessments of top companies - capabilities, results, competition and sales potentials

Our report assesses 43 leading manufacturers of generic medicines worldwide. In general a company profile gives you the following information:

  • Discussion of activities, technologies and recent financial results
  • Assessment of developments - mergers and acquisitions (M&A), new products, outlooks, challenges and plans
  • Forecasting of generic drug revenues to 2025 (for 19 leading companies).

Discover capabilities, progress and prospects of top generics companies, grouped by region, helping you stay ahead in commercial knowledge and influence. Our study explains the changing generics industry from 2015 to 2025, including opportunities.

For the top 50 generic drug manufacturers in 2014, discover revenues and rankings. Also see top companies' gross profit margins, EBITDA margins and historical revenue growth.

The following sections show how our new investigation helps your work.

North America - outlooks for leading generic drug producers and sellers

First our report analyses 13 North American generics specialists and big pharma companies in that market, including these firms:

  • Mylan
  • Pfizer
  • Abbott
  • Hospira
  • Apotex
  • Par Pharmaceuticals.

In that analysis you find where revenue growth occurs and how high sales can go. Many opportunities remain, with high, expanding revenues possible from 2015.

Europe - prospects for leading generics players

Our survey also shows you outlooks for 10 European generics specialists and pharmaceutical leaders in that industry, including these firms:

  • Novartis (Sandoz)
  • Actavis
  • Sanofi
  • Fresenius Kabi
  • Pharmstandard
  • Gedeon Richter
  • Stada Arzneimittel.

The report shows you how companies can seize opportunities and expand their businesses from 2015 to 2025. You also examine organisations competing for shares of that expanding, evolving market.

India - analysis of leading generic drug firms

Our new work also assesses 10 Indian generic drug producers, including these firms:

  • Sun Pharmaceutical Industries
  • Dr. Reddy's Laboratories
  • Lupin
  • Ranbaxy
  • Aurobindo
  • Glenmark
  • Wockhardt.

How much sales growth and geographical expansion can Indian generics companies achieve from 2015? Our study shows you revenue data, trends and prospects, examining what opportunities and potentials exist.

Producers from the rest of world - assess technologies, progress and prospects

Our investigation also shows you outlooks for 10 generic drug makers based in other countries, including these companies:

  • Teva Pharmaceutical Industries
  • EMS
  • Aspen Pharmacare
  • Nichi-Iko
  • Abdi Ibrahim
  • Hypermarcas
  • Eurofarma
  • Sawai Pharmaceuticals.

Countries such as Japan, Brazil and China will become increasingly important for generic drug development, production and sales from 2015 to 2025, our analyses show.

That work explains forces shaping the generics market and industry, helping you explore changes, challenges and opportunities. Discover what the future holds.

Issues affecting generic drug development, manufacturing and sales

Our report discusses issues and events affecting that industry and market from 2015, including these forces:

  • Specialty generics - difficult-to-produce medicines with high profit margins
  • Shift towards innovative and improved drugs, via expanding R&D budgets
  • Mergers and acquisitions (M&A) influencing that expanding healthcare market
  • Big pharma firms targeting generics - diversification of product portfolios
  • International expansion - targeting developed and developing national markets
  • Intellectual property - regulations, challenges and developments
  • Biosimilars - opportunities for generic and originator drug companies.

There you explore the generic drug industry's strengths, weaknesses, opportunities and threats. With our study you discover what the future holds for top generic drug producers.

You also gain our interviews with Sanofi Generics and the Generic Pharmaceutical Association (GPhA). Hear what participants think, say and do, helping you stay ahead.

Ways Top Generic Drug Producers - Leading Companies and Forecasts 2015-2025 - Prospects for Development, Manufacturing and Business Expansion helps

In particular, our new analysis benefits your work in these five main ways:

  • Profiles of 43 generics companies - assess product ranges, strategies and sales results, also gaining revenue forecasts to 2025 for 19 organisations
  • Competition and opportunities - explore what shapes the generic drugs market's future, especially companies' prospects for sustaining and expanding business
  • Analysis of what benefits and restrains generic drug makers - assess challenges and strengths, helping you compete and gain advantages
  • Reviews of established competitors and rising players in the generics sector - explore needs, competition, technologies and outlooks for future success
  • Interviews with authorities - discover what participants in the industry think, say and do, helping you stay ahead in commercial knowledge.

That report, by visiongain's in-house analysts in the UK, gives information to benefit your work, saving you hassle and time. You gain data leading companies depend on.

Knowledge found nowhere else, helping your research, analyses and decisions

Our investigation gives independent analysis. You receive competitive intelligence found only in that report, discovering generics companies with the most commercial promise.

With our new survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions. Also find how you can save time and gain in recognition for insight, benefiting your authority.

Predictions for generic drug production and sales - gain by trying our study now

Our new analysis shows you data, trends, opportunities and sales forecasts for top producers and sellers of generic drugs. Avoid missing out - please get our report here now.

Table of Contents

1. Report Overview

  • 1.1. Introduction to this Survey
  • 1.2. Main Report Findings
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Questions Answered by This Analytical Report
  • 1.6. Who is This Report For?
  • 1.7. Methods of Research and Analysis
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Visiongain Reports
  • 1.10. About Visiongain

2. Top 50 Generic Drug Manufacturers

  • 2.1. Top 50 Generic Drug Manufacturers: Revenues and Ranking, 2014
  • 2.2. Top 50 Generic Drug Companies: Revenue Analysis, 2014
  • 2.3. Top 50 Generic Drug Companies Regional Distribution, 2014
  • 2.4. Report Coverage
  • 2.5. Report Complexity
    • 2.5.1. Obtaining Data from Private Companies
    • 2.5.2. Financial Years Variability
    • 2.5.3. Generics Revenue Identification
    • 2.5.4. Defining Generics 1: Difference Between Biosimilars and Generics
    • 2.5.5. Defining Generics 2: ‘Super-Generics' and APIs
    • 2.5.6. Defining Generics 3: Rx and OTC

3. Top North American Generic Drug Manufacturers: Activities and Prospects, 2015-2025

  • 3.1. Companies Covered in this Chapter
  • 3.2. Leading US Generic Drug Manufacturers: Financial Performance Outline, 2014
  • 3.3. Mylan: Number One US Manufacturer of Generic Drugs: Company Overview, 2015
    • 3.3.1. Mylan Historical Performance and Financial Results Analysis, 2015
    • 3.3.2. Mylan Generic Drugs Revenue Forecast, 2015-2025
    • 3.3.3. First Class II Transdermal Approval Consolidates Mylan's Top Status in the US Market
    • 3.3.4. Tender System Hurts Mylan's German Market Share but the Company Retains its Australian Dominance
    • 3.3.5. Mylan's Focus on Complex Generics: Reasons and Causes
    • 3.3.6. Mylan's Generic Portfolio Remains the Company's Core Strength
    • 3.3.7. Mylan's Winning Acquisition Strategy
    • 3.3.8. Mylan Acquired Abbott: Towards Scale Economies and Vertical Integration
    • 3.3.9. Mylan's Potential Acquisition Plans - Outlook
  • 3.4. Pfizer - The Leading Research-Based Pharmaceutical: Company Overview, 2015
    • 3.4.1. Pfizer Historical Performance and Financial Results Analysis, 2015
    • 3.4.2. Pfizer Generic Drugs Revenue Forecast, 2015-2025
    • 3.4.3. Pfizer Internationalization and Restructuring Strategy
    • 3.4.4. Pfizer's Acquisition of Hospira: A Solution for Boosting the Generic Revenue Stream?
    • 3.4.5. Prospects for Pfizer's Generic Drugs Business
  • 3.5. Abbott: Company Overview, 2015
    • 3.5.1. Abbott Business Segments Performance
    • 3.5.2. Abbott Historical Performance and Financial Results Analysis, 2015
    • 3.5.3. Abbott Generic Drugs Revenue Forecast, 2015-2025
    • 3.5.4. Abbott's Acquisitions: Overview and Analysis, 2010-2014
    • 3.5.5. Abbott's Sale of its Overseas Branded Generic Business: Implications
    • 3.5.6. Future Prospects for Abbott Generic Drugs Business
  • 3.6. Hospira: Company Overview, 2015
    • 3.6.1. Integrated Infusion Therapies and Other Hospira Businesses
    • 3.6.2. Hospira - Injectable Expert Among the Top 10 Generic Companies Acquired by Pfizer
  • 3.7. Apotex: Company Overview, 2015
    • 3.7.1. Apotex Expansion to Europe and Beyond
    • 3.7.2. Apotex Drives Business Diversification Through R&D
  • 3.8. Par Pharmaceuticals: Company Overview, 2015
    • 3.8.1. Par Pharmaceuticals' Acquisition of JPH Group Holdings
    • 3.8.2. Concentrated Generic Revenue Stream and Over 60 Generic Prescription Drugs
    • 3.8.3. Buy Out of Indian Ethics Bio Lab Demonstrates Par's Interest in Niche Products
  • 3.9. Valeant Pharmaceuticals: Company Overview, 2015
    • 3.9.1. Valeant: A Major Challenger in the Emerging Markets
    • 3.9.2. Branded Generics are Crucial to Valeant's Emerging Market Ambitions
    • 3.9.3. Valeant Implements Acquisition Strategy to Boost Revenues
    • 3.9.4. Valeant Generic Drugs Revenue Forecast, 2015-2025
  • 3.10. Endo Pharmaceuticals: Company Overview, 2015
    • 3.10.1. Endo: Pain Expertise in Branded and Generic Drugs
    • 3.10.2. Endo's Expansion on the South African Market
    • 3.10.3. Performance Analysis on Endo's Qualitest Business
    • 3.10.4. Future Prospects for Endo Pharmaceuticals Generic Drugs Business
    • 3.10.5. Endo Generic Drugs Revenue Forecast, 2015-2025
  • 3.11. Pharmascience - Another Major Canadian Player: Company Overview, 2015
    • 3.11.1. Over 200 Generic Product Families
    • 3.11.2. Korean Venture Driving Diversification for Pharmascience
  • 3.12. Mallinckrodt: Company Overview, 2015
    • 3.12.1. Mallinckrodt Generics: Valuable Addition to the Company's Portfolio
    • 3.12.2. Reclassification of Methylphenidate ER Products: Effects on Mallinckrodt's Income
    • 3.12.3. What is Mallinckrodt's Advantage Against Strong Competition?
    • 3.12.4. Partnerships and Acquisitions: Crucial for Mallinckrodt's Rapid Expansion
  • 3.13. Akorn Pharmaceuticals: Company Overview, 2015
    • 3.13.1. Akorn Acquisition of Small Companies: A Strategic Shift Towards Broad Market Reach
    • 3.13.2. Akorn Strengthens its Position on the US Ophthalmology Market
  • 3.14. Alvogen - A Privately-Owned US Company is the One to Watch: Company Overview, 2015
    • 3.14.1. Alvogen Unique Business Model Proves Good Results
    • 3.14.2. Alvogen Target is to Become Top 10 Global Generic Player
  • 3.15. Sagent Pharmaceuticals - One of the Fastest Growing Providers of Specialty Generics in the US: Company Overview, 2015
    • 3.15.1. Will Sagent's Different Business Model Achieve Growth?

4. Top European Generic Drug Manufacturers: Activities and Prospects, 2015-2025

  • 4.1. Companies Covered in this Chapter
  • 4.2. Leading European Generic Drug Manufacturers: Financial Performance Outline, 2014
  • 4.3. CEE Markets Home to Many Big Generic Contenders
  • 4.4. Novartis (Sandoz) - the World's Second Largest Generic Pharmaceutical Company: Overview, 2015
    • 4.4.1. Novartis (Sandoz) Historical Performance and Financial Results Analysis, 2015
    • 4.4.2. Novartis (Sandoz) Generic Drugs Revenue Forecast, 2015-2025
    • 4.4.3. Novartis (Sandoz) Key Developments Analysis, 2015
    • 4.4.4. Europe is the Main Market for Sandoz
    • 4.4.5. Emphasis on Complex, Differentiated Generics and Biosimilars
    • 4.4.6. Future Prospects for Novartis Generic Drugs Business
  • 4.5. Actavis: Company Overview, 2015
    • 4.5.1. Actavis Historical Performance and Financial Results Analysis, 2015
    • 4.5.2. Actavis Generic Drugs Revenue Forecast, 2015-2025
    • 4.5.3. Implications of Actavis Large Product Portfolio
    • 4.5.4. Actavis Customized Commercial Model for International Markets
    • 4.5.5. Merger Creates New Force in the Generic Drug Industry
    • 4.5.6. Actavis Acquisition of Forest Laboratories: Move Towards Specialty Pharmaceuticals
    • 4.5.7. The Acquisition of Auden McKenzie Will Add More than 150 Products to Actavis Product Line
    • 4.5.8. Actavis Acquired Allergan with Aim to be a Top 10 Pharmaceutical Company
  • 4.6. Sanofi: Company Overview, 2015
    • 4.6.1. Sanofi Historical Performance and Financial Results Analysis, 2015
    • 4.6.2. Sanofi Generic Drugs Revenue Forecast, 2015-2025
    • 4.6.3. Adaptive Business Model for Sanofi's Generic Drug Division
    • 4.6.4. Zentiva Benefits from Strong Presence in the EU Market
    • 4.6.5. Future Prospects for Sanofi Generics
  • 4.7. Fresenius Kabi - Leading Generic Intravenous Drug Player: Company Overview, 2015
    • 4.7.1. Intra Venous Drugs: The Main Product Line for Fresenius Kabi
    • 4.7.2. Fresenius Kabi Will Continue to Expand
  • 4.8. Pharmstandard - The Biggest Russian Pharmaceutical Manufacturer: Company Overview, 2015
    • 4.8.1. Acquisitions Strengthen Pharmstandard Manufacturing and Product Base
    • 4.8.2. Pharmstandard Benefits from Strong Organic Production Capacity
    • 4.8.3. Future Prospects for Pharmstandard Generic Drugs Business
    • 4.8.4. Pharmstandard Generic Drugs Revenue Forecast, 2015-2025
  • 4.9. Gedeon Richter - Hungarian Leader Looking Further Afield: Company Overview, 2015
    • 4.9.1. Female Health and Fertility Segments Form Core Strengths for Gedeon Richter
    • 4.9.2. Specialisation Strategy for Further Growth
    • 4.9.3. A Pan-European Pharmaceutical Presence for the Future?
    • 4.9.4. Gedeon Richter Generic Drugs Revenue Forecast, 2015-2025
  • 4.10. Krka - Slovenian Generic Giant Active in 70+ Countries: Company Overview, 2015
    • 4.10.1. Prescription Generics: Krka's Major Focus
    • 4.10.2. Russia is the Largest National Market for Krka, but for How Long?
    • 4.10.3. Krka Generic Drugs Revenue Forecast, 2015-2025
  • 4.11. Stada Arzneimittel - Major Presence in Germany and Central Europe: Company Overview, 2015
    • 4.11.1. Negative Effect from the CIS Region Crisis
    • 4.11.2. Strong Product Development with Over 600 Product Launches in 2014
    • 4.11.3. Stada Targets the Biosimilar Sector with Promising Deals
    • 4.11.4. Stada Arzneimittel Generic Drugs Revenue Forecast, 2015-2025
  • 4.12. Perrigo: Company Overview, 2015
    • 4.12.1. Perrigo Drives Generic Segment Growth through Acquisitions, but Will it be Acquired Itself?
    • 4.12.2. Rx Pharmaceuticals: Main Contributors to Perrigo's Revenue Stream
  • 4.13. Polpharma - Poland's Generic Powerhouse: Company Overview, 2015
    • 4.13.1. Polpharma's Continuous Product Portfolio Enlargement
    • 4.13.2. Strong Regional Presence in Poland, Russia and Kazakhstan
    • 4.13.3. Acquisition Increases Polpharma Dominance in the Polish Market

5. Top Indian Generic Drug Manufacturers: Activities and Prospects, 2015-2025

  • 5.1. Companies Covered in This Chapter
  • 5.2. India: Generics Supplier to the World
  • 5.3. Top 10 Indian Generic Drug Manufacturers: Financial Performance Outline, 2014
  • 5.4. Sun Pharmaceutical - Leader in the Indian Generic Drug Market, Company Overview, 2015
    • 5.4.1. Sun Has a Leading Presence in the Generic Export Market
    • 5.4.2. Mega Acquisitions to Enlarge Sun's Operations?
    • 5.4.3. Sun Pharmaceutical Generic Drugs Revenue Forecast, 2015-2025
  • 5.5. Dr. Reddy's Laboratories: Company Overview, 2015
    • 5.5.1. At the Forefront of the Indian Generic Boom: Dr. Reddy's Revenue Exceeded $2bn in 2014
    • 5.5.2. North America and Russia are the Largest Export Markets for Dr. Reddy's
    • 5.5.3. Alliance with GlaxoSmithKline
    • 5.5.4. Dr. Reddy's Early Leadership in Biosimilar Antibodies
    • 5.5.5. Dr. Reddy's: Generic Drugs Revenue Forecast, 2015-2025
  • 5.6. Lupin - The Most Successful Indian Generic Firm in the US Market: Company Overview, 2015
    • 5.6.1. Lupin's Continuous Portfolio Growth and Focus on Complex Injectables
    • 5.6.2. Strong R&D Investment in New Delivery Systems and Original Products
    • 5.6.3. Lupin Generic Drugs Revenue Forecast, 2015-2025
  • 5.7. Cipla - Mumbai Based Generic Giant: Company Overview, 2015
    • 5.7.1. Generic Copaxone: A Major Product Launch for Cipla
    • 5.7.2. Cipla's Leadership in Anti-Retroviral Drugs and Focus on Key Markets
    • 5.7.3. Chronic Disease: A Significant Target for Cipla
    • 5.7.4. Cipla Generic Drugs Revenue Forecast, 2015-2025
  • 5.8. Ranbaxy -The Second Largest Indian Generic Manufacturer with Sales in 150+ Countries: Company Overview, 2015
    • 5.8.1. Dermatological Therapeutics: Targeted Area of Growth for Ranbaxy
    • 5.8.2. ANDA Applications Giving Promising Opportunities
    • 5.8.3. High Income Stream from the Emerging Markets
    • 5.8.4. Merger with Sun
  • 5.9. Aurobindo - The Largest FDA APIs Supplier, Moved Into Original Drugs: Company Overview, 2015
    • 5.9.1. High-Margin Specialty Generics
    • 5.9.2. ANDA Filings and Approvals by Region, 2014
    • 5.9.3. CRAMS Opportunities
  • 5.10. Glenmark - Specialty Company Still Leveraging Generic Growth: Overview, 2015
    • 5.10.1. Generics Remain Part of Global Growth Strategy for Glenmark
    • 5.10.2. Glenmark Benefits from Africa and Middle East Exports Boom
    • 5.10.3. Glenmark Generic Drugs Revenue Forecast, 2015-2025
  • 5.11. Wockhardt -Increasing Presence in US and Europe Generics Market: Company Overview, 2015
    • 5.11.1. US Market Growth in 2014
    • 5.11.2. Biosimilars, Novel Delivery Systems and Original Drugs will Drive Growth for Wockhardt
  • 5.12. Cadila - Leader in Indian Cardiovascular Market: Company Overview, 2015
    • 5.12.1. Biochem Acquisition Boosts Cadila's Revenue
    • 5.12.2. Increasing Presence in the US Market
    • 5.12.3. Cadila: A Future Biosimilar Force?
  • 5.13. Ipca Laboratories - One of Top 10 Indian Pharma Exporters: Company Overview, 2015
    • 5.13.1. Fast Development Due to Niche Strategic Approach

6. Top Generic Drug Manufacturers from the Rest of the World: Activities and Prospects, 2015-2025

  • 6.1. Companies Covered in this Chapter
  • 6.2. Leading Rest of the World Generic Drug Manufacturers: Financial Performance Outline, 2014
  • 6.3. Japanese and Brazilian Generic Environment Particularly Significant to the Global Generic Drug Market
  • 6.4. Teva Pharmaceutical Industries: Company Overview of the World's Generic Industry Leader, 2015
    • 6.4.1. Teva Historical Performance and Financial Results Analysis, 2010-2014
    • 6.4.2. Teva Generic Drugs Revenue Forecast, 2015-2025
    • 6.4.3. Teva's Global Presence
    • 6.4.4. How did Teva Achieve its Success?
    • 6.4.5. Teva Operational Strategy: Focus on Cost Reduction
    • 6.4.6. The US Market Stagnates but Teva Sustains its Strong Penetration
    • 6.4.7. From Volume to Value Driven Strategy in the European Markets
    • 6.4.8. Teva Strengthens its Position in the Central Nervous System Market Through the Acquisition of Auspex Pharma
    • 6.4.9. Will Mylan Eventually Join Teva's Long Acquisition List?
    • 6.4.10. Future Prospects for Teva Generic Drugs Business
  • 6.5. EMS - Leading the South American Generic Market: Company Overview, 2015
    • 6.5.1. First Brazilian Company to Export Generics to Europe
    • 6.5.2. EMS Has the Most Advanced Latin American R&D Base
  • 6.6. Aspen Pharmacare - South African Giant Continues to Expand: Company Overview, 2015
    • 6.6.1. Ten-Year CAGR to 2014 Exceeds 25%
    • 6.6.2. Philippines Added to Areas of Activity
    • 6.6.3. Continuing Over 30% Dominance in South Africa Generic Market
    • 6.6.4. Asia-Pacific and International Business Main Revenue Contributors in 2014
    • 6.6.5. Europe/CIS and Latin America: Another Major Growth Opportunity for Aspen
    • 6.6.6. Aspen Generic Drugs Revenue Forecast, 2015-2025
  • 6.7. Nichi-Iko: Company Overview, 2015
    • 6.7.1. More Than 900 Generic Products in Nichi-Iko Portfolio
    • 6.7.2. Nichi-Iko Venture with Sanofi Complements Strategy
  • 6.8. Abdi Ibrahim: Turkey's Leading Pharmaceutical Company
    • 6.8.1. Large Product Portfolio Helps to Sustain Market Position
    • 6.8.2. Abdi Ibrahim has a Vast International Scope
  • 6.9. Hypermarcas SA - Brazilian Pharmaceutical and OTC Giant: Company Overview, 2015
    • 6.9.1. Price Increase and High Profit Margins: Would they be Sustainable?
  • 6.10. Eurofarma - Rapidly-Growing Generics Power in Brazil: Company Overview, 2015
    • 6.10.1. Eight Diversified Business Divisions
    • 6.10.2. M&A Extending Latin American Reach for Eurofarma
  • 6.11. Taro Pharmaceuticals - The Second Largest Israeli Pharmaceutical Manufacturer: Company Overview, 2015
    • 6.11.1. FDA Corticosteroid Spray Approval Boosts Taro's Portfolio in 2014
  • 6.12. Towa Pharmaceuticals - Another Big Japanese Player: Company Overview, 2015
    • 6.12.1. Large Number of Generic Products in Towa's Portfolio
    • 6.12.2. Towa's Broad and Expanding Production Capacity
  • 6.13. Sawai Pharmaceuticals - Osaka-Based Generic Leader: Company Overview, 2015
    • 6.13.1. Annual manufacturing Capacity of 10bn Tablets
    • 6.13.2. Cardiovascular Drugs are the Most Significant Therapeutic Area for Sawai
    • 6.13.3. M&A Boosts Sawai's R&D

7. Interviews from Our Survey

  • 7.1. Interview with Jean-Marie Arnaud, Senior Vice President and Head of Sanofi Generics
    • 7.1.1. Sanofi Generics Act with the Expertise of Sanofi Group
    • 7.1.2. Sanofi Uses Innovative and Adapted Business Model Worldwide
    • 7.1.3. Increasing Revenues for Sanofi Generics as the Company Continues to Focus on Emerging Markets and Portfolio Enlargement
    • 7.1.4. A Generic Product is no Longer Just a Pure Copy of an Original
    • 7.1.5. The Usage of Generic Medicines in Europe Can Still be Optimised
    • 7.1.6. A Combination of Strategies Proves Successful in the Generics Industry
  • 7.2. Interview with a Representative of the Generic Pharmaceutical Association (GPhA)
    • 7.2.1. 86% of all Prescriptions in the US are for Generic Drugs
    • 7.2.2. Patent Settlements Provide Higher Savings and Early Market Entry for Generics
    • 7.2.3. The Cost Burden will Increase if the Generic Drug Labelling Rule Changes
    • 7.2.4. Biosimilars - the New Target for Generic Drug Manufacturers

8. Conclusions

  • 8.1. Companies' Growth Strategies
  • 8.2. Why are Big Pharma Companies Targeting Generics?
  • 8.3. Watson and Actavis Merger: The First Major Consolidation for the Generic Drug Industry
  • 8.4. The Changing Dynamics of the Generic Drug Companies
  • 8.5. Big Pharma Business Models Evolve
  • 8.6. Biosimilars Will Have a Transformative Effect on Both Generic and Originator Drug Companies
  • 8.7. Complex Generics with High Entry Barriers Continue to Increase in Importance
  • 8.8. Future Trends for Generic Drug Producers - What's Possible?

List of Tables

  • Table 1.1: Currency Exchange Rates to $US
  • Table 2.1: Top 50 Generic Drug Manufacturers: Revenues ($m) and Ranking 1-25, 2014
  • Table 2.2: Top 50 Generic Drug Manufacturers: Revenues ($m) and Ranking 26-50, 2014
  • Table 2.3: Top 50 Generic Drug Manufacturers: Revenue ($m) and Market Share (%) According to Group Rank, 2014
  • Table 2.4: Regional Distribution of the Top 50 Companies, 2014
  • Table 3.1: Top 10 North American Generic Drug Manufacturers: Revenues ($m) and Ranking, 2014
  • Table 3.2: Mylan: Company Overview, 2015
  • Table 3.3: Mylan: Historical Generic Drugs Revenue ($m), AGR (%), 2010-2014
  • Table 3.4: Mylan: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
  • Table 3.5: Pfizer: Company Overview, 2015
  • Table 3.6: Pfizer: Historical Generic Drugs Revenue ($m), AGR (%), 2010-2014
  • Table 3.7: Pfizer: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
  • Table 3.8: Abbott: Company Overview, 2015
  • Table 3.9: Abbott: Historical Generic Drugs Revenue ($m), AGR (%), 2010-2014
  • Table 3.10: Abbott: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
  • Table 3.11: Hospira: Company Overview, 2015
  • Table 3.12: Apotex: Company Overview, 2015
  • Table 3.13: Par Pharmaceutical: Company Overview, 2015
  • Table 3.14: Valeant Pharmaceuticals: Company Overview, 2015
  • Table 3.15: Valeant: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
  • Table 3.16: Endo Pharmaceuticals: Company Overview, 2015
  • Table 3.17: Endo: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
  • Table 3.18: Pharmascience: Company Overview, 2015
  • Table 3.19: Mallinckrodt: Company Overview, 2015
  • Table 3.20: Akorn Pharmaceuticals: Company Overview, 2015
  • Table 3.21: Alvogen: Company Overview, 2015
  • Table 3.22: Sagent Pharmaceuticals: Company Overview, 2015
  • Table 4.1: Top 10 European Generic Manufacturers: Revenues ($m) and Ranking, 2014
  • Table 4.2: Novartis (Sandoz): Company Overview, 2015
  • Table 4.3: Novartis: Historical Generic Drugs Revenues ($m), AGR (%), 2010-2014
  • Table 4.4: Novartis: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
  • Table 4.5: Actavis: Company Overview, 2015
  • Table 4.6: Actavis: Historical Generic Drugs Revenues ($m), AGR (%), 2011-2014
  • Table 4.7: Actavis: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
  • Table 4.8: Sanofi: Company Overview, 2015
  • Table 4.9: Sanofi: Historical Generic Drugs Revenues ($m), AGR (%), 2010-2014
  • Table 4.10: Sanofi: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
  • Table 4.11: Fresenius Kabi: Company Overview, 2015
  • Table 4.12: Pharmstandard: Company Overview, 2015
  • Table 4.13: Pharmstandard: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
  • Table 4.14: Gedeon Richter: Company Overview, 2015
  • Table 4.15: Gedeon Richter: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
  • Table 4.16: Krka: Company Overview, 2015
  • Table 4.17: Krka: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
  • Table 4.18: Stada: Company Overview, 2015
  • Table 4.19: Stada: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
  • Table 4.20: Perrigo: Company Overview, 2015
  • Table 4.21: Polpharma: Company Overview, 2015
  • Table 5.1: Top 10 Indian Generic Manufacturers: Revenues ($m) and Ranking, 2014
  • Table 5.2: Sun Pharmaceutical: Company Overview, 2015
  • Table 5.3: Sun Pharmaceutical: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
  • Table 5.4: Dr. Reddy's: Company Overview, 2015
  • Table 5.5: Dr. Reddy's: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
  • Table 5.6: Lupin: Company Overview, 2015
  • Table 5.7: Lupin: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
  • Table 5.8: Cipla: Company Overview, 2015
  • Table 5.9: Cipla: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
  • Table 5.10: Ranbaxy: Company Overview, 2015
  • Table 5.11: Ranbaxy: ANDA Filings and Approvals by Region, 2014
  • Table 5.12: Aurobindo: Company Overview, 2015
  • Table 5.13: Aurobindo: ANDAs Filings and Approvals by Region, 2014
  • Table 5.14: Glenmark: Company Overview, 2015
  • Table 5.15: Glenmark: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
  • Table 5.16: Wockhardt: Company Overview, 2015
  • Table 5.17: Cadila: Company Overview, 2015
  • Table 5.18: Ipca: Company Overview, 2015
  • Table 6.1: Top 10 Rest of the World Generic Drug Manufacturers, Revenues ($m) and Ranking, 2014
  • Table 6.2: Teva: Company Overview, 2015
  • Table 6.3: Teva: Historical Generic Drugs Revenues ($m), AGR (%), 2010-2014
  • Table 6.4: Teva: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
  • Table 6.5: Teva: Revenue Breakdown (%) by Region, 2014
  • Table 6.6: Teva: New Generic Drugs Launches by Region, 2014
  • Table 6.7: Teva: Annual Revenue Change (%) in EU5 Countries, 2013-2014
  • Table 6.8: EMS: Company Overview, 2015
  • Table 6.9: Aspen: Company Overview, 2015
  • Table 6.10: Aspen: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025
  • Table 6.11: Nichi-Iko: Company Overview, 2015
  • Table 6.12: Abdi Ibrahim: Company Overview, 2015
  • Table 6.13: Hypermarcas: Company Overview, 2015
  • Table 6.14: Eurofarma: Company Overview, 2015
  • Table 6.15: Taro Pharmaceutical: Company Overview, 2015
  • Table 6.16: Towa Pharmaceutical: Company Overview, 2015
  • Table 6.17: Sawai Pharmaceutical: Company Overview, 2015

List of Figures

  • Figure 2.1: Top 50 Generic Drug Manufacturers: Revenues ($m), 2014
  • Figure 2.2: Generic Drug Manufacturers: Revenue ($m) Comparison by Group Rank, 2014
  • Figure 2.3: Top 50 Generic Drug Manufacturers: Market Share (%) Amongst the Top 50 Companies According to Group Rank, 2014
  • Figure 2.4: Top 10 Generic Drug Manufacturers: Market Share (%) Among the Top 50 Companies, 2014
  • Figure 2.5: Regional Balance Among the Top 50 Generic Drug Manufacturers, 2014
  • Figure 2.6: Biosimilars and Generics: Overview, 2015
  • Figure 3.1: Top 10 North American Generic Drug Manufacturers: Revenues ($m), 2014
  • Figure 3.2: Leading North American Generic Drug Manufacturers: Gross Profit Margin (%), 2014
  • Figure 3.3: Leading North American Generic Drug Manufacturers: EBITDA Margin (%), 2014
  • Figure 3.4: Leading North American Generic Drug Manufacturers: Revenue Growth (%), 2013-2014
  • Figure 3.5: Mylan: Historical Generic Drugs Revenue ($m), AGR (%), 2010-2014
  • Figure 3.6: Mylan: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
  • Figure 3.7: Mylan: Number of Generic Products on Leading European Markets, 2014
  • Figure 3.8: Mylan: Revenue Breakdown (%) by Business Segment, 2014
  • Figure 3.9: Mylan: Revenue Breakdown (%) by Therapeutic Area, 2014
  • Figure 3.10: Pfizer: Historical Generic Drugs Revenue ($m), AGR (%), 2010-2014
  • Figure 3.11: Pfizer: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
  • Figure 3.12: Abbott: Revenue Breakdown (%) by Business Segment, 2014
  • Figure 3.13: Abbott: Historical Generic Drugs Revenue ($m), AGR (%), 2010-2014
  • Figure 3.14: Abbott: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
  • Figure 3.15: Valeant: Revenue Breakdown (%) by Business Segment, 2014
  • Figure 3.16: Valeant: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
  • Figure 3.17: Endo: Revenue Breakdown (%) by Business Segment, 2014
  • Figure 3.18: Endo: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
  • Figure 3.19: Akorn's Major Acquisition: Overview of the Reasons, 2015
  • Figure 4.1: Top 10 European Generic Manufacturers: Revenues ($m), 2014
  • Figure 4.2: Leading European Generic Drug Manufacturers: Gross Profit Margin (%), 2014
  • Figure 4.3: Leading European Generic Drug Manufacturers: EBITDA Margin (%), 2014
  • Figure 4.4: Leading European Generic Drug Manufacturers: AGR (%), 2013-2014
  • Figure 4.5: Novartis: Revenue Breakdown by Business Segment, 2014
  • Figure 4.6: Novartis: Historical Generic Drugs Revenues ($m), AGR (%), 2010-2014
  • Figure 4.7: Novartis: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
  • Figure 4.8: Sandoz: Revenue Breakdown by Region, 2014
  • Figure 4.9: Sandoz: Revenue Breakdown by Business Segment, 2014
  • Figure 4.10: Actavis Sales Breakdown (%), 2014
  • Figure 4.11: Actavis: Historical Generic Drugs Revenues ($m), AGR (%), 2011-2014
  • Figure 4.12: Actavis: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
  • Figure 4.13: Actavis Sales Breakdown (%), 2014
  • Figure 4.14: Sanofi: Generic Drugs Revenue Breakdown by Region, 2014
  • Figure 4.15: Sanofi: Historical Generic Drugs Revenues ($m), AGR (%), 2010-2014
  • Figure 4.16: Sanofi: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
  • Figure 4.17: Pharmstandard: Revenue Breakdown by Business Segment, 2014
  • Figure 4.18: Pharmstandard: Export Sales Breakdown by Country, 2014
  • Figure 4.19: Pharmstandard: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
  • Figure 4.20: Gedeon Richter: Revenue Breakdown by Therapeutic Segment, 2014
  • Figure 4.21: Gedeon Richter: Revenue Breakdown by Country, 2014
  • Figure 4.22: Gedeon Richter: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
  • Figure 4.23: Krka: Revenue Breakdown by Business Segment, 2014
  • Figure 4.24: Krka: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
  • Figure 4.25: Stada: Revenue Breakdown (%) by Business Segment, 2014
  • Figure 4.26: Stada: Revenue Breakdown by Region, 2014
  • Figure 4.27: Stada: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
  • Figure 4.28: Perrigo Company: Revenue Breakdown by Business Segment, 2014
  • Figure 5.1: Top 10 Indian Generic Manufacturers: Revenues ($m), 2014
  • Figure 5.2: Top 10 Indian Generic Drug Manufacturers: Gross Profit Margin (%), 2014
  • Figure 5.3: Top 10 Indian Generic Drug Manufacturers: EBITDA Margin (%), 2014
  • Figure 5.4: Top 10 Indian Generic Drug Manufacturers: Revenue AGR (%), 2013-2014
  • Figure 5.5: Sun Pharmaceutical: Revenue Breakdown (%) by Business Segment, 2014
  • Figure 5.6: Sun Pharmaceutical: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
  • Figure 5.7: Dr. Reddy's: Revenue Breakdown (%) by Business Segment, 2014
  • Figure 5.8: Dr. Reddy's: Revenue Breakdown (%) by Region, 2014
  • Figure 5.9: Dr. Reddy's: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
  • Figure 5.10: Lupin: Revenue Breakdown (%) by Markets, 2014
  • Figure 5.11: Lupin: Revenue Breakdown (%) by Therapeutic Area, 2014
  • Figure 5.12: Lupin: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
  • Figure 5.13: Cipla: Revenue Breakdown (%) by Region, 2014
  • Figure 5.14: Cipla: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
  • Figure 5.15: Ranbaxy: Revenue Breakdown (%) by Markets, 2014
  • Figure 5.16: Glenmark: Sales Revenue Increase (%) by Region, 2013-2014
  • Figure 5.17: Glenmark: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
  • Figure 5.18: Wockhardt: Revenue Breakdown (%) by Region, 2014
  • Figure 5.19: Ipca: Revenue Breakdown (%) by Therapeutic Area, 2014
  • Figure 6.1: Top 10 Rest of the World Generic Manufacturers: Revenues ($m), 2014
  • Figure 6.2: Leading Rest of the World Generic Drug Manufacturers: Gross Profit Margin (%), 2014
  • Figure 6.3: Leading Rest of the World Generic Drug Manufacturers: EBITDA Margin (%), 2014
  • Figure 6.4: Leading Rest of the World Generic Drug Manufacturers: AGR (%), 2013-2014
  • Figure 6.5: Teva: Revenue Breakdown (%) by Business Segment, 2014
  • Figure 6.6: Teva: Historical Generic Drugs Revenues ($m), AGR (%), 2010-2014
  • Figure 6.7: Teva: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
  • Figure 6.8: Teva: Revenue Breakdown by Region, 2014
  • Figure 6.9: Teva: New Generic Drug Launches by Region, 2014
  • Figure 6.10: Teva: Annual Revenue Change (%) in EU5 Countries, 2013-2014
  • Figure 6.11: Aspen: Revenue Breakdown (%) by Region, 2013 and 2014
  • Figure 6.12: Aspen: Revenue Increase (%) by Region, 2014
  • Figure 6.13: Aspen: European Revenue Breakdown (%) by Region, 2014
  • Figure 6.14: Aspen: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025
  • Figure 6.15: Taro Pharmaceutical: Revenue Breakdown (%) by Region, 2014

Companies Listed

  • Abbott
  • AbbVie
  • Abdi Ibrahim
  • Abrika Pharmaceuticals
  • Ache
  • Actavis
  • Active Pharma
  • Adcock Ingram
  • Advance Vision Research
  • Aegera
  • Afrexa Life Sciences
  • Agouron Pharmaceuticals
  • Akorn Pharmaceuticals
  • Akrikhin
  • Alcon
  • Allergan
  • Alpharma
  • Alvogen
  • AmerisourceBergen
  • Amide
  • Amneal Pharmaceuticals
  • AMS
  • APL Holdings Limited
  • ApoPharma
  • Apotex
  • Apotex Fermentation
  • APP Pharmaceuticals
  • Aprogen
  • Arrow Group
  • Asahi Kasei Pharma Corporation
  • Ascent Pharmahealth
  • ASKA Pharmaceutical
  • Aspen
  • Aspen Pharmacare
  • Aspen Trading
  • AstraZeneca
  • Auden McKenzie
  • Aurigene Discovery Technologies
  • Auro Pharma
  • Aurobindo
  • Balkanpharma
  • Barr Pharmaceuticals
  • Bausch and Lomb Holdings
  • Bayer
  • Bayer Yakuhin
  • BeiKang Pharmaceutical
  • Bever
  • Biocad Holding
  • Bioniche Pharma
  • Biovena
  • Boca Pharmacal
  • Boehringer Ingelheim
  • Brainfarma Industria e Farmaceutica
  • Bremer Pharma
  • Bunker and Delta
  • Cadila Healthcare
  • Cardinal Health
  • Cenova Pharma
  • CFR Pharmaceuticals
  • Chatted
  • Chattem Chemicals
  • Chimpharm
  • Chiron Corporation
  • Chirotech Technology
  • CIBA VISION
  • Cipla
  • CNS Therapeutics
  • Colotech
  • Cosmed Industria de Cosmeticos e Medicamentos S.A.
  • D. Searle & Company
  • Dabur Pharma
  • DACA Pharmaceuticals
  • Daichi Kasei
  • Dialfor Health
  • DKSH
  • Dr. Reddy's Laboratories
  • Dream Pharma
  • Dusa Pharmaceuticals
  • EBEWE Pharma
  • Elan Pharmaceuticals
  • Elder Pharmaceuticals
  • Emcure
  • Emergent Biosolutions
  • Emploi Quebec
  • European Medicines Agency
  • EMS
  • Endo
  • Eon Labs
  • Ethics Bio Lab
  • Eurofarma
  • Facet Biotech
  • Fako
  • Fenwal
  • Filaxis
  • Fougera Pharmaceuticals
  • Fresenius Kabi
  • Fuso Pharmaceutical Industries
  • Gangene Corp
  • Gedeon Richter
  • Generic Health
  • Generic Pharmaceutical Association (GPhA)
  • Genfar S.A.
  • Genzyme
  • Germa Pharm
  • GlaxoSmithKline (GSK)
  • Glenmark
  • Globalpharma
  • Golden Cross Pharma
  • Greenstone
  • Handok
  • HealthTronics
  • Helvepharm
  • Herbapol Pruszkow
  • Hexa
  • Hikma
  • Hi-Tech Pharmacal
  • Hospira
  • Hypermarcas
  • IDEV Technologies
  • Ikaria
  • Innopharma
  • Inspire Pharmaceuticals
  • Investissement Quebec
  • Ipca Laboratories
  • J-DOLPH Pharmaceutical
  • Johnson & Johnson
  • JPH Group Holdings
  • Kanghong Sagen Pharmaceuticals
  • Keri Pharma
  • Kilitch Drugs
  • Kolmar Holdings
  • Krka
  • Kunwha Pharmaceuticals
  • Kyowa Pharmaceuticals
  • Labesfal
  • Laboratorio Sanderson
  • Laboratorios Gautier
  • Laboratorios Grin
  • Laboratorios Kendrick
  • Labormed Pharma
  • Leek
  • Lekko
  • Les Laboratoires Servier SAS
  • Lotus Pharmaceuticals
  • Lupin
  • mAbxience
  • Madaus
  • Mallinckrodt
  • Maruko Pharmaceutical
  • Masterlek
  • McKesson Drug Company
  • Mechnikov Biomed
  • Mediate Specialities
  • Medina
  • Medisa Shinyaku
  • Medley Industria Farmaceutica
  • Meiji Seika Pharma
  • Merck & Co
  • Microdose
  • Mitani Sangyo
  • Mitsubishi Tanabe Pharma
  • MJ Pharma
  • Multicare
  • Mylan Laboratories
  • Nanomi B.V
  • National Druggists
  • NBZ Pharma Limited
  • Negma
  • Nichi-Iko
  • Nichi-Iko Pharma Tech
  • Nicox
  • Nippon Chemipher
  • Nippon Kayaku
  • NIXS Corporation
  • Novartis
  • Nycomed
  • Oak Pharmaceuticals
  • OctoPlus
  • Omega Laboratories Limited
  • Onset Dermatologics
  • Onyx
  • Oriel Therapeutics
  • Orion
  • Paladin Labs
  • Par Pharmaceutical
  • Parke-Davis
  • Pendopharm
  • Perrigo Company
  • Pfizer
  • PGT Healthcare
  • Pharma Avalanche
  • Pharmacin
  • Pharmapark
  • Pharmascience
  • Pharmascience Korea
  • PharmaSwiss
  • Pharmstandard
  • Pharmstandard Biotec
  • Phlox Pharma
  • Pinewood Laboratories
  • Piramal Healthcare Solutions
  • Polfa Warszawa
  • Polpharma
  • Pradeep Drug Company
  • Promius Pharma
  • Pymepharco
  • Qalitest
  • Questcor
  • Ranbaxy Laboratories
  • Ranbaxy Life Sciences Research
  • Ratiopharm
  • Ribbon
  • Richter-Helm
  • Roche
  • Romark Laboratories
  • Sabex
  • Sagent Acquisition Corp
  • Salix Pharmaceuticals
  • Sandoz
  • Sanofi
  • Sanofi Pasteur
  • Sawai Pharmaceuticals
  • Schein Pharmaceutical
  • Sekisui Medical
  • Shantha Biotechnics
  • Silom Medical Company
  • Sindan
  • Solus Pharmaceuticals
  • Solvay Pharmaceuticals
  • Somar
  • Specifar Pharmaceuticals S.A.
  • SPIL de Mexico
  • Spirig Pharma
  • Stada Arzneimittel
  • STARLIMS
  • Sun Pharmaceutical
  • Swisse Wellness
  • Taiyo Cephalon
  • Taro
  • Technologies Inc
  • Teikoku Medix
  • Terapia S.A.
  • Teva Pharmaceutical Industries
  • The European Generic Medicines Association (EGA)
  • The Generic Pharmaceutical Association
  • TKS Pharmaceutical
  • Torrent Pharmaceuticals
  • Towa
  • UDL Laboratories
  • United Research Laboratories
  • URL Pharma
  • US Food and Drug Administration (FDA)
  • Uteron Pharma S.A.
  • Valeant
  • Velefarm
  • Veropharm
  • VersaPharm Incorporated
  • Vindexpharm
  • VPI Holdings Corp
  • Warner Chilcott
  • Warner Lambert
  • Watson Pharmaceuticals
  • Winthrop
  • Wockhardt
  • Wyeth
  • Yakuhan Pharmaceuticals
  • ZAO Ranbaxy
  • Zao Sun Pharma
  • Zhejiang Chiral Medicine Chemicals Company
  • ZiO Zdorovje
  • Zoetis
  • Zydus Pharmaceuticals
  • Zydus Wellness
Back to Top